Viewing Study NCT03507166


Ignite Creation Date: 2025-12-24 @ 4:13 PM
Ignite Modification Date: 2026-01-09 @ 11:29 AM
Study NCT ID: NCT03507166
Status: COMPLETED
Last Update Posted: 2019-08-21
First Post: 2018-04-08
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer
Sponsor: RemeGen Co., Ltd.
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Urothelial Carcinoma View
None Advanced Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None RC48-ADC View
None HER2 View